
Novel Drug Delivery Systems Industry Research Report 2025
Description
Summary
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
According to APO Research, The global Novel Drug Delivery Systems market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Novel Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Novel Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Novel Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Novel Drug Delivery Systems include Amgen, Teva, Roche, UCB (Union Chimique Belge), Celgene, Merck, Gilead Sciences, Sanofi and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Novel Drug Delivery Systems Segment by Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Novel Drug Delivery Systems Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein–drug Conjugates
Others
Novel Drug Delivery Systems Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
Novel Drug Delivery Systems Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
Novel Drug Delivery Systems Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Novel Drug delivery System (NDDS) refers to the approaches, formulations, technologies, and systems for transporting a pharmaceutical compound in the body as needed to safely achieve its desired therapeutic effects. NDDS is a system for delivery of drug other than conventional drug delivery system. NDDS is a combination of advance technique and new dosage forms which are far better than conventional dosage forms.
Advantages of Novel Drug Delivery System are: Optimum dose at the right time and right location, efficient use of expensive drugs, excipients and reduction in production cost, Beneficial to patients, better therapy, improved comfort and standard of living.
According to APO Research, The global Novel Drug Delivery Systems market was valued at US$ million in 2024 and is anticipated to reach US$ million by 2031, witnessing a CAGR of xx% during the forecast period 2025-2031.
North American market for Novel Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Asia-Pacific market for Novel Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
Europe market for Novel Drug Delivery Systems is estimated to increase from $ million in 2025 to reach $ million by 2031, at a CAGR of % during the forecast period of 2025 through 2031.
The major global companies of Novel Drug Delivery Systems include Amgen, Teva, Roche, UCB (Union Chimique Belge), Celgene, Merck, Gilead Sciences, Sanofi and Pfizer, etc. In 2024, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Novel Drug Delivery Systems, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Novel Drug Delivery Systems.
The Novel Drug Delivery Systems market size, estimations, and forecasts are provided in terms of revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Novel Drug Delivery Systems market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided. For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
Key Companies & Market Share Insights
In this section, the readers will gain an understanding of the key players competing. This report has studied the key growth strategies, such as innovative trends and developments, intensification of product portfolio, mergers and acquisitions, collaborations, new product innovation, and geographical expansion, undertaken by these participants to maintain their presence. Apart from business strategies, the study includes current developments and key financials. The readers will also get access to the data related to global revenue, price, and sales by manufacturers for the period 2020-2025. This all-inclusive report will certainly serve the clients to stay updated and make effective decisions in their businesses.
Novel Drug Delivery Systems Segment by Company
Amgen
Teva
Roche
UCB (Union Chimique Belge)
Celgene
Merck
Gilead Sciences
Sanofi
Pfizer
Takeda
Bausch&Lomb
Samyang Biopharmaceuticals
Johnson & Johnson
TOLMAR
Astellas
AMAG Pharmaceuticals
AbbVie
Dr Reddy
AstraZeneca
Aspen
Acrotech Biopharma
TWi Pharmaceuticals
Novel Drug Delivery Systems Segment by Type
Liposomes
PEGylated Proteins & Polypeptides
Polymer Nanoparticle
Protein–drug Conjugates
Others
Novel Drug Delivery Systems Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
Novel Drug Delivery Systems Segment by Application
Hospitals & Clinic
Cancer Treatment Centers
Others
Novel Drug Delivery Systems Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Novel Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Novel Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Novel Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Novel Drug Delivery Systems companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
Please Note: Single-User license will be delivered via PDF from the publisher without the rights to print or to edit.
Table of Contents
122 Pages
- 1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
- 2 Market Overview
- 2.1 Product Definition
- 2.2 Novel Drug Delivery Systems by Type
- 2.2.1 Market Value Comparison by Type (2020 VS 2024 VS 2031)
- 2.2.2 Liposomes
- 2.2.3 PEGylated Proteins & Polypeptides
- 2.2.4 Polymer Nanoparticle
- 2.2.5 Protein–drug Conjugates
- 2.2.6 Others
- 2.3 Novel Drug Delivery Systems by Application
- 2.3.1 Market Value Comparison by Application (2020 VS 2024 VS 2031)
- 2.3.2 Hospitals & Clinic
- 2.3.3 Cancer Treatment Centers
- 2.3.4 Others
- 2.4 Assumptions and Limitations
- 3 Novel Drug Delivery Systems Breakdown Data by Type
- 3.1 Global Novel Drug Delivery Systems Historic Market Size by Type (2020-2025)
- 3.2 Global Novel Drug Delivery Systems Forecasted Market Size by Type (2026-2031)
- 4 Novel Drug Delivery Systems Breakdown Data by Application
- 4.1 Global Novel Drug Delivery Systems Historic Market Size by Application (2020-2025)
- 4.2 Global Novel Drug Delivery Systems Forecasted Market Size by Application (2026-2031)
- 5 Global Growth Trends
- 5.1 Global Novel Drug Delivery Systems Market Perspective (2020-2031)
- 5.2 Global Novel Drug Delivery Systems Growth Trends by Region
- 5.2.1 Global Novel Drug Delivery Systems Market Size by Region: 2020 VS 2024 VS 2031
- 5.2.2 Novel Drug Delivery Systems Historic Market Size by Region (2020-2025)
- 5.2.3 Novel Drug Delivery Systems Forecasted Market Size by Region (2026-2031)
- 5.3 Novel Drug Delivery Systems Market Dynamics
- 5.3.1 Novel Drug Delivery Systems Industry Trends
- 5.3.2 Novel Drug Delivery Systems Market Drivers
- 5.3.3 Novel Drug Delivery Systems Market Challenges
- 5.3.4 Novel Drug Delivery Systems Market Restraints
- 6 Market Competitive Landscape by Players
- 6.1 Global Top Novel Drug Delivery Systems Players by Revenue
- 6.1.1 Global Top Novel Drug Delivery Systems Players by Revenue (2020-2025)
- 6.1.2 Global Novel Drug Delivery Systems Revenue Market Share by Players (2020-2025)
- 6.2 Global Novel Drug Delivery Systems Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Novel Drug Delivery Systems Head Office and Area Served
- 6.4 Global Novel Drug Delivery Systems Players, Product Type & Application
- 6.5 Global Novel Drug Delivery Systems Manufacturers Established Date
- 6.6 Global Novel Drug Delivery Systems Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
- 7 North America
- 7.1 North America Novel Drug Delivery Systems Market Size (2020-2031)
- 7.2 North America Novel Drug Delivery Systems Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 7.3 North America Novel Drug Delivery Systems Market Size by Country (2020-2025)
- 7.4 North America Novel Drug Delivery Systems Market Size by Country (2026-2031)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
- 8 Europe
- 8.1 Europe Novel Drug Delivery Systems Market Size (2020-2031)
- 8.2 Europe Novel Drug Delivery Systems Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 8.3 Europe Novel Drug Delivery Systems Market Size by Country (2020-2025)
- 8.4 Europe Novel Drug Delivery Systems Market Size by Country (2026-2031)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
- 9 Asia-Pacific
- 9.1 Asia-Pacific Novel Drug Delivery Systems Market Size (2020-2031)
- 9.2 Asia-Pacific Novel Drug Delivery Systems Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 9.3 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2020-2025)
- 9.4 Asia-Pacific Novel Drug Delivery Systems Market Size by Country (2026-2031)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
- 10 South America
- 10.1 South America Novel Drug Delivery Systems Market Size (2020-2031)
- 10.2 South America Novel Drug Delivery Systems Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 10.3 South America Novel Drug Delivery Systems Market Size by Country (2020-2025)
- 10.4 South America Novel Drug Delivery Systems Market Size by Country (2026-2031)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
- 11 Middle East & Africa
- 11.1 Middle East & Africa Novel Drug Delivery Systems Market Size (2020-2031)
- 11.2 Middle East & Africa Novel Drug Delivery Systems Market Growth Rate by Country: 2020 VS 2024 VS 2031
- 11.3 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2020-2025)
- 11.4 Middle East & Africa Novel Drug Delivery Systems Market Size by Country (2026-2031)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
- 12 Players Profiled
- 12.1 Amgen
- 12.1.1 Amgen Company Information
- 12.1.2 Amgen Business Overview
- 12.1.3 Amgen Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.1.4 Amgen Novel Drug Delivery Systems Product Portfolio
- 12.1.5 Amgen Recent Developments
- 12.2 Teva
- 12.2.1 Teva Company Information
- 12.2.2 Teva Business Overview
- 12.2.3 Teva Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.2.4 Teva Novel Drug Delivery Systems Product Portfolio
- 12.2.5 Teva Recent Developments
- 12.3 Roche
- 12.3.1 Roche Company Information
- 12.3.2 Roche Business Overview
- 12.3.3 Roche Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.3.4 Roche Novel Drug Delivery Systems Product Portfolio
- 12.3.5 Roche Recent Developments
- 12.4 UCB (Union Chimique Belge)
- 12.4.1 UCB (Union Chimique Belge) Company Information
- 12.4.2 UCB (Union Chimique Belge) Business Overview
- 12.4.3 UCB (Union Chimique Belge) Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.4.4 UCB (Union Chimique Belge) Novel Drug Delivery Systems Product Portfolio
- 12.4.5 UCB (Union Chimique Belge) Recent Developments
- 12.5 Celgene
- 12.5.1 Celgene Company Information
- 12.5.2 Celgene Business Overview
- 12.5.3 Celgene Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.5.4 Celgene Novel Drug Delivery Systems Product Portfolio
- 12.5.5 Celgene Recent Developments
- 12.6 Merck
- 12.6.1 Merck Company Information
- 12.6.2 Merck Business Overview
- 12.6.3 Merck Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.6.4 Merck Novel Drug Delivery Systems Product Portfolio
- 12.6.5 Merck Recent Developments
- 12.7 Gilead Sciences
- 12.7.1 Gilead Sciences Company Information
- 12.7.2 Gilead Sciences Business Overview
- 12.7.3 Gilead Sciences Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.7.4 Gilead Sciences Novel Drug Delivery Systems Product Portfolio
- 12.7.5 Gilead Sciences Recent Developments
- 12.8 Sanofi
- 12.8.1 Sanofi Company Information
- 12.8.2 Sanofi Business Overview
- 12.8.3 Sanofi Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.8.4 Sanofi Novel Drug Delivery Systems Product Portfolio
- 12.8.5 Sanofi Recent Developments
- 12.9 Pfizer
- 12.9.1 Pfizer Company Information
- 12.9.2 Pfizer Business Overview
- 12.9.3 Pfizer Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.9.4 Pfizer Novel Drug Delivery Systems Product Portfolio
- 12.9.5 Pfizer Recent Developments
- 12.10 Takeda
- 12.10.1 Takeda Company Information
- 12.10.2 Takeda Business Overview
- 12.10.3 Takeda Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.10.4 Takeda Novel Drug Delivery Systems Product Portfolio
- 12.10.5 Takeda Recent Developments
- 12.11 Bausch&Lomb
- 12.11.1 Bausch&Lomb Company Information
- 12.11.2 Bausch&Lomb Business Overview
- 12.11.3 Bausch&Lomb Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.11.4 Bausch&Lomb Novel Drug Delivery Systems Product Portfolio
- 12.11.5 Bausch&Lomb Recent Developments
- 12.12 Samyang Biopharmaceuticals
- 12.12.1 Samyang Biopharmaceuticals Company Information
- 12.12.2 Samyang Biopharmaceuticals Business Overview
- 12.12.3 Samyang Biopharmaceuticals Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.12.4 Samyang Biopharmaceuticals Novel Drug Delivery Systems Product Portfolio
- 12.12.5 Samyang Biopharmaceuticals Recent Developments
- 12.13 Johnson & Johnson
- 12.13.1 Johnson & Johnson Company Information
- 12.13.2 Johnson & Johnson Business Overview
- 12.13.3 Johnson & Johnson Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.13.4 Johnson & Johnson Novel Drug Delivery Systems Product Portfolio
- 12.13.5 Johnson & Johnson Recent Developments
- 12.14 TOLMAR
- 12.14.1 TOLMAR Company Information
- 12.14.2 TOLMAR Business Overview
- 12.14.3 TOLMAR Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.14.4 TOLMAR Novel Drug Delivery Systems Product Portfolio
- 12.14.5 TOLMAR Recent Developments
- 12.15 Astellas
- 12.15.1 Astellas Company Information
- 12.15.2 Astellas Business Overview
- 12.15.3 Astellas Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.15.4 Astellas Novel Drug Delivery Systems Product Portfolio
- 12.15.5 Astellas Recent Developments
- 12.16 AMAG Pharmaceuticals
- 12.16.1 AMAG Pharmaceuticals Company Information
- 12.16.2 AMAG Pharmaceuticals Business Overview
- 12.16.3 AMAG Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.16.4 AMAG Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
- 12.16.5 AMAG Pharmaceuticals Recent Developments
- 12.17 AbbVie
- 12.17.1 AbbVie Company Information
- 12.17.2 AbbVie Business Overview
- 12.17.3 AbbVie Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.17.4 AbbVie Novel Drug Delivery Systems Product Portfolio
- 12.17.5 AbbVie Recent Developments
- 12.18 Dr Reddy
- 12.18.1 Dr Reddy Company Information
- 12.18.2 Dr Reddy Business Overview
- 12.18.3 Dr Reddy Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.18.4 Dr Reddy Novel Drug Delivery Systems Product Portfolio
- 12.18.5 Dr Reddy Recent Developments
- 12.19 AstraZeneca
- 12.19.1 AstraZeneca Company Information
- 12.19.2 AstraZeneca Business Overview
- 12.19.3 AstraZeneca Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.19.4 AstraZeneca Novel Drug Delivery Systems Product Portfolio
- 12.19.5 AstraZeneca Recent Developments
- 12.20 Aspen
- 12.20.1 Aspen Company Information
- 12.20.2 Aspen Business Overview
- 12.20.3 Aspen Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.20.4 Aspen Novel Drug Delivery Systems Product Portfolio
- 12.20.5 Aspen Recent Developments
- 12.21 Acrotech Biopharma
- 12.21.1 Acrotech Biopharma Company Information
- 12.21.2 Acrotech Biopharma Business Overview
- 12.21.3 Acrotech Biopharma Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.21.4 Acrotech Biopharma Novel Drug Delivery Systems Product Portfolio
- 12.21.5 Acrotech Biopharma Recent Developments
- 12.22 TWi Pharmaceuticals
- 12.22.1 TWi Pharmaceuticals Company Information
- 12.22.2 TWi Pharmaceuticals Business Overview
- 12.22.3 TWi Pharmaceuticals Revenue in Novel Drug Delivery Systems Business (2020-2025)
- 12.22.4 TWi Pharmaceuticals Novel Drug Delivery Systems Product Portfolio
- 12.22.5 TWi Pharmaceuticals Recent Developments
- 13 Report Conclusion
- 14 Disclaimer
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.